Endoglin (CD105) is a target for an oral DNA vaccine against breast cancer

@article{Lee2006EndoglinI,
  title={Endoglin (CD105) is a target for an oral DNA vaccine against breast cancer},
  author={Sung-Hyung Lee and Noriko Mizutani and Masato Mizutani and Yunping Luo and He Zhou and Charles D. Kaplan and S Kim and Rong Xiang and Ralph A. Reisfeld},
  journal={Cancer Immunology, Immunotherapy},
  year={2006},
  volume={55},
  pages={1565-1574}
}
Endoglin (CD105), a co-receptor in the TGF-β receptor complex, is over-expressed on proliferating endothelial cells in the breast tumor neovasculature and thus offers an attractive target for anti-angiogenic therapy. Here we report the anti-angiogenic/anti-tumor effects achieved in a prophylactic setting with an oral DNA vaccine encoding murine endoglin, carried by double attenuated Salmonella typhimurium (dam −, AroA − ) to a secondary lymphoid organ, i.e., Peyer’s patches . We demonstrate… CONTINUE READING